Skip to main content
JADPRO Live 2024 Main banner
Icon Legend
ICONS KEY
CE Credit Available
CE Credit Available
Pharmacology Credit Available
Pharmacology Credit Available
Poster Activities
Poster Activities
Surgical Oncology
Surgical Oncology
Back

JADPRO Live 2024

On-Demand: Updates in HR-Positive, HER2-Negative Metastatic Breast Cancer for the Advanced Practitioner

Wednesday, November 20, 2024
Location: Grapevine Ballroom
CE: 0.75 credits/hours

Disclosures:

Kathryn Newlin has served on an advisory board for Biotheranostics, Inc., a Hologic Company.
Sanita Burgic has no relevant financial relationships to disclose.

Learning Objectives:

  • Recall the mechanisms of action of recently approved and emerging drugs and biologics used to treat patients with HR+/HER2- metastatic breast cancer (mBC)
  • Match the names of new drugs used to treat HR+/HER2- mBC with their FDA-approved label indications
  • Safely manage treatment-related adverse events in patients with HR+/HER2- mBC who are receiving newly approved and emerging drugs and biologics
  • Identify treatment options for HR+ HER2- mBC